Cytogenetic risk stratification in chronic myelomonocytic leukemia

Esperanza Such,[1] José Cervera,[1] Dolors Costa,[2] Francesc Solé,[3] Teresa Vallespí,[4] Elisa Luño,[5] Rosa Collado,[6] María J. Calasanz,[7] Jesús M. Hernández-Rivas,[8] Juan C. Cigudosa,[9] Benet Nomdedeu,[2] Mar Mallo,[3] Felix Carbonell,[6] Javier Bueno,[4] María T. Ardanaz,[10] Fernando Ramos,[11] Mar Tormo,[12] Reyes Sancho-Tello,[13] Consuelo del Cañizo,[8] Valle Gómez,[14] Victor Marco,[15] Blanca Xicoy,[16] Santiago Bonanad,[17] Carmen Pedro,[3] Teresa Bernal,[5] and Guillermo F. Sanz[1]

[1]Hospital Universitario La Fe, Valencia; [2]Hospital Clinic, Barcelona; [3]Hospital del Mar, Barcelona; [4]Hospital Universitario Vall D'Hebron, Barcelona; [5]Hospital Central de Asturias, Oviedo; [6]Hospital General de Valencia; [7]Universidad de Navarra, Pamplona; [8]Hospital Universitario de Salamanca; [9]Centro Nacional de Investigaciones Oncológicas, Madrid; [10]Hospital Txagorritxu, Vitoria; [11]Complejo Hospitalario, and IBIOMED Universidad de León; [12]Hospital Clínico Universitario, Valencia; [13]Hospital Arnau de Villanova, Valencia; [14]Hospital La Princesa, Madrid; [15]Hospital Arnau de Vilanova, Lleida; [16]Hospital Germans Trias i Pujol, Badalona; and [17]Hospital de la Ribera, Valencia, Spain

Online Supplementary Table S1. Overall survival and risk of AML evolution according to the new CMML-specific and the IPSS cytogenetic risk classifications in patients with MD-CMML and MP-CMML subtypes.

Characteristic	N. of patients (%)	Overall Survival		P	Time to 25% probability (mo)	AML evolution		P
		Median (mo)	Proportion Alive at 2 yr (%)			Cumulative probability of AML evolution (%)		
						At 2 yr	At 5 yr	
CMML- MD								
CMML-specific cytogenetic risk classification				<0.001				0.016
Good risk	210	49	89		66	10	16	
Intermediate risk	23	30	69		8	19	30	
Poor risk	22	12	55		6	33	33	
IPSS cytogenetic risk classification				< 0.001				0.028
Low risk	215	48	70		66	10	16	
Intermediate risk	32	14	46		13	27	27	
High risk	8	9	42		7	25	25	
CMML- MP								
CMML-specific cytogenetic risk classification				< 0.001				0.022
Good risk	113	23	47		28	15	44	
Intermediate risk	19	11	27		5	16	58	
Poor risk	29	10	14		6	48	48	
IPSS cytogenetic risk classification				0.001				0.043
Low risk	114	23	47		28	15	44	
Intermediate risk	36	6	18		13	29	64	
High risk	11	15	28		6	47	47	

BM: bone marrow; PB: peripheral blood; IPSS: International Prognostic Scoring System.

A

B

——— Low risk
·········· Intermediate risk
— · — · High risk

Risk Groups	P value
Low vs. Intermediate	0.06
Low vs. High	< 0.001
Intermediate vs. High	0.08

Risk Groups	P value
Low vs. Intermediate	0.028
Low vs. High	< 0.001
Intermediate vs. High	0.15

C

D

Risk Groups	P value
Low vs. Intermediate	0.12
Low vs. High	< 0.001
Intermediate vs. High	0.15

Risk Groups	P value
Low vs. Intermediate	0.001
Low vs. High	0.15
Intermediate vs. High	0.65